Steris vs Zimmer Biomet
STE and ZBH side by side, both in surgical, medical, and dental instruments and supplies. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How STE and ZBH compare
Steris is the larger company, worth 1.2 times as much as Zimmer Biomet ($22.1B against $18.0B).
On earnings, Zimmer Biomet is cheaper: it trades at 23.0× trailing earnings, against 27.8× for Steris.
Zimmer Biomet grew revenue faster over the last twelve months (8.6% versus 8.4% for Steris).
Steris keeps more of each dollar of sales as profit, with a net margin of 13.3% compared with 9.5% at Zimmer Biomet.
Both pay dividends: Steris yields 0.86% and Zimmer Biomet 1.0%.
Steris scores higher on the StockData Score (21 against 17 for Zimmer Biomet), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | STE | ZBH |
|---|---|---|
| Size and price | ||
| Market cap | $22.1B | $18.0B |
| Share price | $227.12 | $94.52 |
| Change, 1 year | −4.1% | −5.2% |
| Change, 5 years | 1.1% | −33.3% |
| Beta (5Y) | 0.77 | 0.69 |
| Employees | 17K | 17K |
| StockData Score | ||
| Total score | 21 (better) | 17 |
| Valuation score | 4 | 6 (better) |
| Growth score | 3 (better) | 1 |
| Performance score | 4 (better) | 3 |
| Health score | 6 (better) | 3 |
| Dividend score | 4 | 4 |
| Valuation | ||
| P/E | 27.8× | 23.0× (better) |
| P/S | 3.7× | 2.1× (better) |
| P/B | 3.1× | 1.4× (better) |
| EV/EBITDA | 14.4× | 10.9× (better) |
| P/FCF | 23.9× | 11.8× (better) |
| PEG | 0.29 (better) | 0.48 |
| FCF yield | 4.2% | 8.4% (better) |
| Fair value | $255.07 | $124.06 |
| Margin of safety | 11.0% | 23.8% (better) |
| Growth | ||
| Revenue growth (TTM) | 8.4% | 8.6% (better) |
| Revenue growth, 5Y average | 13.8% (better) | 6.1% |
| Net income growth (TTM) | 24.5% (better) | −2.0% |
| EPS growth (TTM) | 25.5% (better) | 0.00% |
| EPS growth, 5Y average | 11.4% | – |
| Profitability | ||
| Gross margin | 44.4% | 69.9% (better) |
| Operating margin | 18.9% (better) | 14.2% |
| Net margin | 13.3% (better) | 9.5% |
| FCF margin | 15.3% | 17.9% (better) |
| Return on equity | 11.4% (better) | 6.4% |
| Return on invested capital | 9.9% (better) | 5.3% |
| Financial health | ||
| Debt / equity | 0.26 (better) | 0.59 |
| Net debt / EBITDA | 0.86 (better) | 3.06 |
| Interest coverage | 18.8× | – |
| Current ratio | 1.91 (better) | 1.69 |
| Altman Z-score | 5.23 (better) | 2.46 |
| Piotroski F-score | 9 (better) | 6 |
| Dividends and buybacks | ||
| Dividend yield | 0.86% | 1.0% (better) |
| Payout ratio | 30.7% | 23.4% |
| Years of dividend growth | 9 (better) | 0 |
| Dividend growth, 5Y average | 9.4% (better) | 0.00% |
| Buyback yield | 1.5% | 4.2% (better) |
| Shareholder yield | 2.4% | 5.2% (better) |
| Ownership | ||
| Held by institutions | 97.4% | 104% |
| Held by insiders | 0.34% | 0.18% |
| Insider net buying, 12 months | −$9.8M | −$1.6M (better) |
| Superinvestors holding | – | 1 |
| Short interest, % of float | 2.9% | 5.1% |
Go deeper
- STE stock overview
- STE income statement
- STE valuation and score
- ZBH stock overview
- ZBH income statement
- ZBH valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.